Abstract
Objective
Study design
Results
Conclusions
Implications
Keywords
1. Introduction
- Directorate General of Family Planning, Ministry of Health and Family Welfare
- National Institute of Population Research and Training (Bangladesh)
2. Materials and methods
2.1 Sampling of pharmacies
2.2 Rapid assessment survey
2.3 Mystery client visit
3. Results
3.1 Knowledge of pharmacy workers

3.2 Practice of the pharmacy workers

Characteristics | Rapid assessment survey, n (%) | Mystery client visit, n (%) | p value |
---|---|---|---|
Asked client about LMP | n=538 (%) | n=548 (%) | |
Yes | 448 (83) | 478 (87) | |
No | 90 (17) | 13 (70) | .07 |
Referred client for MR Services | n=538 (%) | n=302 (%) | |
Yes | 523 (97) | 89 (29) | |
No | 15 (3) | 213 (71) | <.01 |
Characteristics | Rapid assessment survey, n (%) | Mystery client visit, n (%) | p value |
---|---|---|---|
Procedure suggested for MR | n=526 (%) | n=548 (%) | |
MVA with syringe at health facility | 504 (96) | 329 (60) | <.01 |
MRM at home/facility | 471 (89) | 439 (80) | <.01 |
Medicines offered to the clients for MR services | n=380 (%) | n=213 (%) | |
Misoprostol | 137 (36) | 7 (3) | <.01 |
Mifepristone | 15 (4) | 0 (0) | <.01 |
Mifepristone–misoprostol combination | 344 (90) | 213 (100) | <.01 |
Other drugs | 22 (6) | 2 (1) | <.01 |
Mife–miso combination provided | n=349 (%) | n=213 (%) | |
Following recommended dosage | 126 (36) | 114 (53) | |
Did not follow recommended dosage | 95 (27) | 44 (21) | |
Following provider's prescription | 128 (37) | 55 (26) | <.01 |
Suggested route of administration of mifepristone–misoprostol combination | n=221 (%) | n=158 (%) | |
Oral only | 17 (8) | 6 (4) | |
Oral and buccal/sublingual | 204 (92) | 152 (96) | .13 |
Characteristics | Rapid assessment survey, n (%) | Mystery client visit, n (%) | p value |
---|---|---|---|
Informed about effectiveness of mife–miso | n=349 (%) | n=213 (%) | |
Yes | 245 (70) | 90 (42) | |
No | 104 (30) | 123 (58) | <.01 |
Indications of effectiveness of mife–miso | n=245 (%) | n=90 (%) | |
Bleeding | 245 (100) | 90 (100) | .99 |
Abdominal cramp | 114 (46) | 25 (28) | <.01 |
Counseled on side effects of mife–miso | n=187 (%) | n=22 (%) | |
Diarrhea | 13 (7) | 2 (9) | .66 |
Nausea/vomiting | 123 (66) | 12 (55) | .34 |
Fever/chills | 59 (31) | 9 (41) | .47 |
Headache/vertigo | 131 (70) | 15 (68) | .81 |
Informed about follow-up visit | n=349 (%) | n=213 (%) | |
Yes | 175 (50) | 25 (12) | |
No | 174 (50) | 188 (88) | <.01 |
Characteristics | Rapid assessment survey, n (%) | Mystery client visit, n (%) | p value |
---|---|---|---|
Counseled on | |||
Complications of mifepristone–misoprostol | n=349 (%) | n=213 (%) | |
Yes | 221 (63) | 24 (11) | |
No | 128 (37) | 189 (89) | <.01 |
Complications of using mifepristone–misoprostol | n=221 (%) | n=24 (%) | |
Excessive bleeding | 214 (97) | 22 (92) | .21 |
Severe abdominal pain | 76 (34) | 7 (29) | .65 |
Infection (fever >1 day) | 13 (6) | 0 (0) | .62 |
Where to go in case of complication | n=221 (%) | n=24 (%) | |
Referral | 219 (99) | 23 (96) | |
No referral | 2 (1) | 1 (4) | .26 |
Places of referral for complication management | n=219 (%) | n=23 (%) | |
Government hospital | 57 (26) | 4 (17) | .45 |
Private clinic/hospital | 97 (44) | 5 (22) | .04 |
NGO clinic | 79 (36) | 4 (17) | .10 |
Another pharmacy | 32 (15) | 7 (30) | .06 |
Counseled on post-MR contraceptives | n=349 (%) | n=213 (%) | |
Yes | 165 (47) | 11 (5) | |
No | 184 (53) | 202 (95) | <.01 |
4. Discussion
Acknowledgments
References
- Scaled up and marginalized: a review of Bangladesh's menstrual regulation programme and its impact.in: Blas E. Sommerfeld J. Kurup A.S. Social determinants approaches to public health: from concept to practice. World Health Organization (WHO), Geneva2011: 9-24
- Directorate general of family planning, Bangladesh National Menstrual Regulation Service Guidelines, 2014. Directorate General of Family Planning and World Health Organization (WHO) Country Office for Bangladesh; and Amsterdam: Kingdom of the Netherlands, Dhaka, Bangladesh2014
- Current status and access to abortion: the Bangladesh experience.in: Klugman B. Budlender D. Advocating for abortion access: eleven country studies. Women's Health Project, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa2001
- Population control and family planning division. Memo no. 5-14/MCH-FP/Trg./M.R. Programme. Government of the People's Republic of Bangladesh, Dacca1979
- A situation analysis of the menstrual regulation programme in Bangladesh.Reprod Health Matters. 2004; 12: 95-104
- Menstrual regulation and postabortion care in Bangladesh: factors associated with access to and quality of services.Guttmacher Insitute, New York2012
- Organogram and job description [in Bengali].http://www.dgfpbd.orgDate accessed: August 15, 2017
- Family welfare visitors' training institutes (FWVTIs): course description.http://www.niport.gov.bd/document/training/Basic-Training.pdfDate accessed: August 17, 2017
- Directorate general of family planning: MCH-services unit. Memorandum no.: DGFP/MCH-RH/pro-sha (admin) 23/05/108.2015
- The incidence of menstrual regulation procedures and abortion in Bangladesh, 2010.Int Perspect Sex Reprod Health. 2012; 38: 122-132
- Bangladesh demographic and health survey 2014.NIPORT, Mitra and Associates, and ICF International, Dhaka, Bangladesh, and Rockville, Maryland, USA2016
- Ordeal of women for induced abortion in a rural area of Bangladesh.J Health Popul Nutr. 2001; 19: 281-290
- ‘Having another child would be a life or death situation for her’: understanding pregnancy termination among couples in rural Bangladesh.Am J Public Health. 2008; 98: 1827-1832
- STD management by private pharmacies in Hanoi: practice and knowledge of drug sellers.Sex Transm Infect. 2000; 76: 299-302
- The practice of STI treatment among chemists and druggists in Pokhara.Nepal Sex Transm Infect. 2002; 78: 223-226
- Commercial availability of misoprostol and induced abortion in Brazil.Int J Gynaecol Obstet. 1998; 63: S131-S139
- Standards for the establishment and operations of model pharmacies and model medicine shops. Government of the People's Republic of Bangladesh. Ministry of Health and Family Welfare (MoH&FW). Directorate General of Drug Administration (DGDA), Dhaka2016
- Availability and provision of misoprostol and other medicines for menstrual regulation among pharmacies in Bangladesh via mystery client survey.Int J Gynaecol Obstet. 2014; 124: 164-168
- Pharmacy provision of medical abortifacients in a Latin American city.Contraception. 2006; 74: 394-399
- The simulated client method: evaluating client–provider interactions in family planning clinics.Stud Fam Plann. 1993; 24: 187-193
- Undercover careseekers: simulated clients in the study of health provider behavior in developing countries.Soc Sci Med. 1997; 45: 1465-1482
- Delivering medical abortion at scale: a study of the retail market for medical abortion in Madhya Pradesh, India.PLoS One. 2015; 10: e0120637https://doi.org/10.1371/journal.pone.0120637
- SAAF: a harm reduction approach to improve access to MRM.
- Ectopic pregnancy in the era of medical abortion: are we ready for it? Spectrum of sonographic findings and our experience in a tertiary care service hospital of India.J Obstet Gynaecol India. 2013; 63: 388-393
Article info
Publication history
Footnotes
☆Potential referees/peer reviewers
☆1. Hillary Bracken
☆Senior Director
☆Gynuity Health Projects
☆15 East 26th Street, Suite 801
☆New York, NY 10010
☆Phone: 212.448.1230
☆Email: [email protected]
☆2. Laura Reichenbach
☆Senior Associate & Deputy Technical Director
☆The Evidence Project
☆Population Council
☆Washington, DC
☆Email: [email protected]
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy